This review highlights the development of 2A and 3C protease inhibitors as potential antiviral therapies for picornaviral infections.
No takes yet. Share an insight, caveat, or question.
Novel 2A/3C inhibitor designs may inform antiviral development; leaves open clinical translation for picornaviral infections.
Q. May Wang (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: